Lexicon Pharmaceuticals (LXRX) Total Debt (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Total Debt for 17 consecutive years, with $49.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Debt fell 50.66% year-over-year to $49.7 million; the TTM figure through Mar 2026 stood at $49.7 million (down 50.66% YoY), while the FY2025 annual figure was $54.0 million, down 46.16% from the prior year.
• Total Debt slipped to $49.7 million in Q1 2026 per LXRX's latest filing, from $54.0 million in the prior quarter.
• Across five years, Total Debt topped out at $100.7 million in Q1 2025 and bottomed at $23.5 million in Q1 2022.
• Historically, Total Debt has averaged $69.6 million across 5 years, with a median of $56.5 million in 2025.
• Annual changes were most pronounced in 2023 — Total Debt soared 318.64% — and 2026, when it sank 50.66%.
• Lexicon Pharmaceuticals' Total Debt stood at $48.6 million in 2022, then surged by 104.84% to $99.5 million in 2023, then rose by 0.79% to $100.3 million in 2024, then tumbled by 46.16% to $54.0 million in 2025, then retreated by 8.0% to $49.7 million in 2026.
• Business Quant data shows LXRX's Total Debt at $49.7 million in Q1 2026, $54.0 million in Q4 2025, and $56.5 million in Q3 2025.